Stocks and Investing Stocks and Investing
Mon, March 4, 2024

Raghuram Selvaraju Reiterated (BBIO) at Strong Buy and Held Target at $47 on, Mar 4th, 2024


Published on 2024-10-28 09:26:05 - WOPRAI, Raghuram Selvaraju
  Print publication without navigation


Raghuram Selvaraju of HC Wainwright & Co., Reiterated "BridgeBio Pharma, Inc." (BBIO) at Strong Buy and Held Target at $47 on, Mar 4th, 2024.

Raghuram has made no other calls on BBIO in the last 4 months.



There are 3 other peers that have a rating on BBIO. Out of the 3 peers that are also analyzing BBIO, 1 agrees with Raghuram's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Kostas Biliouris of "BMO Capital" Initiated at Hold and Held Target at $37 on, Wednesday, January 31st, 2024


These are the ratings of the 2 analyists that currently disagree with Raghuram


  • David Lebowitz of "Citigroup" Maintained at Strong Buy with Increased Target to $46 on, Friday, February 23rd, 2024
  • Josh Schimmer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $50 on, Monday, January 22nd, 2024
Contributing Sources